

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

ETAS ID: TM860343

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	SECURITY INTEREST		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Urotronic, Inc.		12/08/2023	Corporation: DELAWARE
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	JPMorgan Chase Bank, N.A.		
<b>Street Address:</b>	10 South Dearborn		
<b>Internal Address:</b>	IL1-1145		
<b>City:</b>	Chicago		
<b>State/Country:</b>	ILLINOIS		
<b>Postal Code:</b>	60603		
<b>Entity Type:</b>	National Banking Association: UNITED STATES		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Registration Number:</b>	6069695	OPTILUME	
<b>Registration Number:</b>	6080990	UROTRONIC	
<b>Registration Number:</b>	7091781	OPTILUME BPH	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	2024083141		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	2024083141		
<b>Email:</b>	jean.paterson@cscglobal.com		
<b>Correspondent Name:</b>	CSC		
<b>Address Line 1:</b>	1090 Vermont Avenue, NW		
<b>Address Line 4:</b>	Washington, D.C. 20005		
<b>NAME OF SUBMITTER:</b>	Jean Paterson		
<b>SIGNATURE:</b>	/jep/		
<b>DATE SIGNED:</b>	12/12/2023		
<b>Total Attachments: 6</b>			
source=12-12-2023 Urotronic_Inc_TM#page2.tif			
source=12-12-2023 Urotronic_Inc_TM#page3.tif			
source=12-12-2023 Urotronic_Inc_TM#page4.tif			

CH \$90.00 6069695

source=12-12-2023 Urotronic\_Inc\_TM#page5.tif

source=12-12-2023 Urotronic\_Inc\_TM#page6.tif

source=12-12-2023 Urotronic\_Inc\_TM#page7.tif

TRADEMARK SECURITY AGREEMENT dated as of December 8, 2023 (this “**Agreement**”), among the undersigned Loan Party (the “**Grantor**”) and JPMorgan Chase Bank, N.A. (“**JPMorgan**”), as Administrative Agent.

Reference is made to (i) the Credit Agreement dated as of February 12, 2020 (as amended by Amendment and Waiver No. 1, dated as of November 18, 2020, Amendment No. 2 to Credit Agreement, dated as of January 7, 2022, Amendment No. 3 to Credit Agreement, dated as of June 27, 2023 and as further amended, restated, amended and restated, extended, supplemented or otherwise modified from time to time, the “**Credit Agreement**”), among Invifed 8 AB, a company incorporated under the laws of Sweden (“**Holdings**”), LM US Parent, Inc., a Delaware corporation (the “**U.S. Borrower**”), Laborie Medical Technologies Canada ULC, an unlimited liability company incorporated under the laws of British Columbia (the “**Canadian Borrower**”), Medical Measurement Systems B.V., a private limited liability company (*besloten vennootschap met beperkte aansprakelijkheid*) having its official seat (*statutaire zetel*) in Enschede, the Netherlands, registered with the Dutch trade register under number 06070224 (the “**Dutch Borrower**” and, together with the U.S. Borrower and the Canadian Borrower, collectively, the “**Borrowers**” and each a “**Borrower**”), the Lenders and the Issuing Banks from time to time party thereto and JPMorgan, as Administrative Agent, and (ii) the Collateral Agreement dated as of February 12, 2020 (as supplemented by Supplement No. 1, dated as of November 6, 2020, as supplemented by Supplement No. 2, dated as of November 12, 2021, as supplemented by Supplement No. 3, dated as of June 8, 2022, as supplemented by Supplement No. 4, dated as of December 8, 2023, and as further amended, restated, amended and restated, extended, supplemented or otherwise modified from time to time, the “**Collateral Agreement**”), among Holdings, LB Yankee Inc., a Delaware corporation, LM US Parent, Inc., the U.S. Borrower, the other Subsidiary Grantors from time to time party thereto and JPMorgan, as Administrative Agent. The Lenders and Issuing Banks have agreed to extend credit to the Borrowers on the terms and subject to the conditions set forth in the Credit Agreement. The obligations of the Lenders and the Issuing Banks to extend such credit are conditioned upon, among other things, the execution and delivery of this Agreement. The Grantor is an Affiliate of the Borrowers, will derive substantial benefits from the extension of credit to the Borrowers pursuant to the Credit Agreement and are willing to execute and deliver this Agreement in order to induce the Lenders and the Issuing Banks to extend such credit. Accordingly, the parties hereto agree as follows:

## **1 Terms**

Each capitalized term used but not otherwise defined herein shall have the meaning specified in the Credit Agreement or the Collateral Agreement, as applicable. The rules of construction specified in Section 1.3 of the Credit Agreement also apply to this Agreement, mutatis mutandis.

## **2 Grant of Security Interest**

As security for the payment or performance, as the case may be, in full of the Secured Obligations, the Grantor pursuant to the Collateral Agreement or the applicable Security Document did, and hereby does, grant to the Administrative Agent, its successors and assigns, for the benefit of the Secured Parties, a security interest (the “**Security Interest**”) in all right, title and interest in, to and under any and all of the following assets now owned or at any time hereafter acquired by the Grantor or in, to or under which the Grantor now has or at any time hereafter may acquire any right, title or interest to (collectively, the “**Trademark Collateral**”):

- (i) all trademarks, service marks, trade names, corporate names, company names, business names, fictitious business names, trade styles, trade dress, logos, domain

names, global top level domain names, other source or business identifiers, designs and general intangibles of like nature, all registrations and recordings thereof, and all registration and recording applications filed in connection therewith, including registrations and registration applications in the United States Patent and Trademark Office or any similar offices in any State of the United States or any other country or any political subdivision thereof, all extensions or renewals thereof, and all common law rights related thereto, including those listed on Schedule I;

- (ii) all goodwill associated therewith or symbolized thereby; and
- (iii) all other assets, rights and interests that uniquely reflect or embody such goodwill.

Notwithstanding anything herein to the contrary, the Trademark Collateral shall not include, and in no event shall the Security Interest attach to, any intent-to-use Trademark applications filed in the United States Patent and Trademark Office, pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. Section 1051, prior to the accepted filing of a "Statement of Use" and issuance of a "Certificate of Registration" pursuant to Section 1(d) of the Lanham Act or an accepted filing of an "Amendment to Allege Use" whereby such intent-to-use Trademark application is converted to a "use in commerce" application pursuant to Section 1(c) of the Lanham Act, solely to the extent, if any, that, and solely during the period, if any, in which, the grant of a security interest therein would impair the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law.

### **3 Collateral Agreement and other Security Documents**

The security interests granted to the Administrative Agent herein are granted in furtherance, and not in limitation of, the security interests granted to the Administrative Agent pursuant to the Collateral Agreement or the applicable Security Document. The Grantor hereby acknowledges and affirms that the rights and remedies of the Administrative Agent with respect to the Trademark Collateral are more fully set forth in the Collateral Agreement or the applicable Security Document, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein. In the event of any conflict between the terms of this Agreement and the Collateral Agreement or the applicable Security Document, the terms of the Collateral Agreement or such Security Document, as applicable, shall govern.


### **4 Counterparts**

This Agreement may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page of this Agreement by facsimile or other electronic imaging shall be effective as delivery of a manually executed counterpart of this Agreement.

*[Signature Pages Follow]*

**In Witness Whereof**, the parties hereto have duly executed this Agreement as of the day and year first above written.

**UROTRONIC, INC.,**

By:  \_\_\_\_\_

Name: Paul Haydock  
Title: Chief Financial Officer

By: \_\_\_\_\_

Name: George Stacey  
Title: Secretary


**In Witness Whereof**, the parties hereto have duly executed this Agreement as of the day and year first above written.

**UROTRONIC, INC.,**

By: \_\_\_\_\_

Name: Paul Haydock

Title: Chief Financial Officer

By:  \_\_\_\_\_

Name: George Stacey

Title: Secretary

**JPMORGAN CHASE BANK, N.A.,**  
as Administrative Agent

By: *Erica C Lorenzo*  
Name: Erica C Lorenzo  
Title: Authorized Officer

## SCHEDULE I

### Trademarks and Trademark Licenses

Title	Jurisdiction	Application No. / Serial No.	Owner
OPTILUME	Canada	TMA1,005,723	Urotronic, Inc.
OPTILUME	USA	6,069,695	Urotronic, Inc.
UROTRONIC	USA	6,080,990	Urotronic, Inc.
OPTILUME BPH	Canada	2,220,541	Urotronic, Inc.
OPTILUME BPH	USA	7,091,781	Urotronic, Inc.